Drugs and Valvular Heart Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1 This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, valvular heart disease is associated with anorectic agents, such as fenfluramine, and antimigraine medications, such as ergot-amine, via serotonin 5-HT2B receptor agonism66.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [66]
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Self-citationAppetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 53
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Self-citation
Cited by
Items 201–300 of 503
Żółkowska, D., Baumann, M. H., & Rothman, R. B. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132654 · Cited by 36
“When stimulated, these cells undergo mitogenesis that leads to excessive growth culminating in valvulopathy (for review, see Roth, 2007 ).”
Orally Inhaled Dihydroergotamine: A Review
Tepper, S. J. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12184 · Cited by 32
“The ergot valvular fibrosis involves mitogenicity via pathways initiated by 5-HT2B agonists.(42) Dr.”
BackgroundNew Pharmacological Treatments for the Management of Obesity
Hurt, R. T., Varayil, J. E., & Ebbert, J. O. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0394-0 · Cited by 39
Marin, P., Bécamel, C., Chaumont‐Dubel, S., Vandermoere, F., Bockaert, J., & Claeysen, S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00005-0 · Cited by 46
“Activation of 5-HT2B receptor is responsible for abnormal echocardiograms, pulmonary hypertension, cardiac valve deficiencies triggered by the fenfluramine metabolite norfenfluramine, a drug inducing a weight loss initially marketed by Wyeth (Roth, 2007).”
BackgroundFolding Underlies Bidirectional Role of GPR37/Pael-R in Parkinson Disease
Leinartaité, L., & Svenningsson, P. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.006 · Cited by 32
Current treatment options for hyperprolactinemia
Faje, A. T., & Nachtigall, L. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.806488 · Cited by 31
“Experiments suggest that activation of 5-HT2B receptors stimulates valvular interstitial cell proliferation and can lead to overgrowth valvulopathy [103].”
BackgroundRosa, L. P., da Silva, F. C., Viana, M. S., & Meira, G. A. (2015) · Lasers in Medical Science · doi:10.1007/s10103-015-1826-2 · Cited by 31
McIntyre, R. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2248883 · Cited by 32
Dose Dependency and Reversibility of Serotonin-Induced Valvular Heart Disease in Rats
Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M. A., Franken, P. R., et al. (2009) · Cardiovascular Toxicology · doi:10.1007/s12012-009-9046-2 · Cited by 32
“The serotonin 2B (5HT2B) receptor is thought to be the main pathway through which these drugs activate valvular fibroblasts to produce glycosaminoglycans and collagen leading to valvular thickening and regurgitation [18, 19].”
BackgroundDérumeaux, G., Ernande, L., Sérusclat, A., Servan, E., Bruckert, É., ROUSSET, H., Senn, S. J., Gaal, L. V., Picandet, B., Gavini, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038273 · Cited by 32
MANAGEMENT OF ENDOCRINE DISEASE: GH excess: diagnosis and medical therapy
Andersen, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0532 · Cited by 29
Guiding lead optimization with GPCR structure modeling and molecular dynamics
Heifetz, A., James, T., Morao, I., Bodkin, M. J., & Biggin, P. C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.06.004 · Cited by 29
Psychedelics and Anti-inflammatory Activity in Animal Models
Flanagan, T. W., & Nichols, C. D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_367 · Cited by 32
Pulmonary Valve Anatomy and Abnormalities
Jonas, S. N., Kligerman, S. J., BURKE, A. P., Frazier, A. A., & WHITE, C. S. (2015) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000182 · Cited by 29
Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor
Wang, Q., Zhou, Y., Huang, J., & Huang, N. (2021) · Pharmaceuticals · doi:10.3390/ph14020076 · Cited by 30
“Additionally, the signaling mechanism of drug-induced VHD has been studied [2,20].”
BackgroundKozikowski, A. P., Cho, S. J., Jensen, N. H., Allen, J. A., Svennebring, A. M., & Roth, B. L. (2010) · ChemMedChem · doi:10.1002/cmdc.201000186 · Cited by 28
Self-citationKochanowska-Karamyan, A. J., ARAÚJO, H. C., Zhang, X., El‐Alfy, A. T., de Carvalho, P. B., Avery, M. A., Holmbo, S. D., Magolan, J., & Hamann, M. T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01107 · Cited by 27
Role of echocardiography in toxic heart valvulopathy
Droogmans, S., Kerkhove, D., Cosyns, B., & Camp, G. V. (2009) · European Journal of Echocardiography · doi:10.1093/ejechocard/jep023 · Cited by 28
Zhang, G., Cheng, J., McCorvy, J. D., Lorello, P. J., Caldarone, B. J., Roth, B. L., & Kozikowski, A. P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00584 · Cited by 30
Self-citationRole of dopamine agonists in Parkinson's disease therapy
Woitalla, D., Buhmann, C., Hilker-Roggendorf, R., Höglinger, G. U., Koschel, J., Müller, T. H., & Weise, D. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02647-0 · Cited by 26
Moritz, A. E., Free, R. B., Weiner, W. S., Akano, E. O., Gandhi, D. M., Abramyan, A. M., Keck, T. M., Ferrer, M., Hu, X., Southall, N. T., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00424 · Cited by 26
Vroonen, L., Lancellotti, P., Garcia, M. T., Dulgheru, R., Rubio-Almanza, M., Maiga, I., Magné, J., Pétrossians, P., Auriemma, R. S., Daly, A., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1120-5 · Cited by 28
“mitogenesis and proliferation of fibroblasts progressively lead to an overgrowth valvulopathy [3, 4].”
BackgroundCheng, J., & Kozikowski, A. P. (2015) · ChemMedChem · doi:10.1002/cmdc.201500437 · Cited by 28
Lorcaserin for the treatment of obesity
Redman, L. M., & Ravussin, É. (2010) · Drugs of today · doi:10.1358/dot.2010.46.12.1556433 · Cited by 33
“5-HT2B receptors are located on cardiac vessels and cardiac valves (8, 9) and activation of these receptors is believed to result in heart valvulopathy and pulmonary hypertension (10).”
BackgroundRestrictive organic mitral regurgitation associated with benfluorex therapy
Tribouilloy, C. M., Ruşinaru, D., Henon, P., Tribouilloy, L., Leleu, F., Andréjak, M., Sevestre, H., Peltier, M., & Caus, T. (2010) · European Journal of Echocardiography · doi:10.1093/ejechocard/jeq027 · Cited by 29
Low‐dose cabergoline causing valvular heart disease in a patient treated for prolactinoma
Cawood, T., Bridgman, P. G., Hunter, L., & Cole, D. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.01920.x · Cited by 26
Smith, P. R., Cole, R., Hamilton, S., West, K., Morley, S. R., & Maskell, P. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw061 · Cited by 25
Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach
Mann, W. A. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02399.x · Cited by 27
Rothman, R. B., Żółkowska, D., & Baumann, M. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.042 · Cited by 26
Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00169.x · Cited by 26
“Since these drugs have high affinity for 5-HT2B receptors, the pathogenesis of valvular disease may involve abnormal serotoninergic fibrogenesis mediated by the 5-HT2B receptors expressed in the fibroblasts of heart valves [12–14].”
BackgroundEffect of (−)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice
Rowland, N. E., Crump, E. M., NGUYEN, N., ROBERTSON, K., Sun, Z., & BOOTH, R. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.004 · Cited by 24
“…with psychomimetic (hallucinogenic) effects (Nichols, 2004) and 5-HT2B activation can lead to valvular heart disease (Connolly et al.,1997; Fitzgerald et al., 2000; Rothman et al., 2000; Setola et al., 2005; Roth, 2007) and pulmonary hypertension (Pouwels et al., 1990; Launay et al., 2002).”
BackgroundAnalysis of secondary pharmacology assays received by the US Food and Drug Administration
Scott, C. C., Dodson, A., Saulnier, M., Snyder, K., & Racz, R. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107205 · Cited by 28
Tye, H., Mueller, S. G., Prestle, J., Scheuerer, S., Schindler, M., Nosse, B., Prévost, N., Brown, C. J., Heifetz, A., Moeller, C., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.089 · Cited by 23
Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Brea, J. M., Castro-Palomino, J. C., Yeste, S., Cubero, E., Parraga, A., Domínguez, E., & Loza, M. I. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791111524 · Cited by 23
“Although the specific details are not yet known, G proteins may activate mitogenic pathways, either by inducing Src phosphorylation (forming Src-P) or by activating extracellular regulated kinases (ERK) [70].”
BackgroundTosh, D. K., Ciancetta, A., Warnick, E., Crane, S., Gao, Z., & Jacobson, K. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01183 · Cited by 24
Budayr, A., Tan, T. C., Lo, J. C.-M., Zaroff, J. G., Tabada, G. H., Yang, J., & Go, A. S. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0507-8 · Cited by 23
Phentermine cardiovascular safety
Rothman, R. B., & Hendricks, E. J. (2009) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2009.07.014 · Cited by 25
“Valvulopathic drugs, including fenfluramines, ergotamine, methysergide, pergolide, and cabergoline, are known to induce damage because they are potent agonists of cardiac 5-HT2B receptors [7,8].”
Background2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery
Bender, A. M., Parr, L. C., Livingston, W. B., Lindsley, C. W., & Merryman, W. D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01178 · Cited by 24
Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo
Huang, X., Che, T., Mangano, T. J., Rouzic, V. L., Pan, Y., Majumdar, S., Cameron, M. D., Baumann, M. H., Pasternak, G. W., & Roth, B. L. (2017) · JCI Insight · doi:10.1172/jci.insight.97222 · Cited by 25
“It is conceivable that W-18 and W-15 are prodrugs that require metabolic transformation for their effects in humans, as has been seen for toxic pharmaceuticals, including fenfluramine (16) and methysergide (17).”
BackgroundSelf-citationNeto, J. X., Soares-Rachetti, V. D. P., Albuquerque, E. L., Manzoni, V., & Fulco, U. L. (2018) · New Journal of Chemistry · doi:10.1039/c7nj03645k · Cited by 23
Sherlock, M., Toogood, A. A., & Steeds, R. P. (2009) · Heart · doi:10.1136/hrt.2008.163345 · Cited by 23
“the ventricular and atrial valve surfaces and the subvalvular apparatus, including the chordae tendineae.(6) Roth showed that norfenfluramine is a potent agonist of the 5HT2B receptor.”
BackgroundReid, T.-E. R., Kumar, K., & Wang, X. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990039 · Cited by 23
Ergotamine and nicergoline – Facts and myths
Zajdel, P., Bednarski, M., Sapa, J., & Nowak, G. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.10.010 · Cited by 21
“Valvulopathy Yes Yes on stenosis related to the antiparkinsonian drugs pergolide and cabergoline were presented, and, in 2007, the Food and Drug Administration issued a market withdrawal of pergolide [13].”
BackgroundLi, G., Yang, L., Xu, Y., Wang, W., Li, L., & Yang, S. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.07.005 · Cited by 21
Dopamine agonists in prevention of ovarian hyperstimulation syndrome
Kasum, M., Vrčić, H., Stanić, P., Ježek, D., Orešković, S., Beketić-Orešković, L., & Pekez, M. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.943716 · Cited by 21
“not stimulate the serotonin receptor subtype 5-HT2b HT2b at relevant concentrations and therefore may be clinically useful [32].”
BackgroundPsychedelics: preclinical insights provide directions for future research
Gumpper, R. H., & Roth, B. L. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01567-7 · Cited by 21
“We [83] and others [84] demonstrated that drugs that induce valvular heart disease in humans after chronic administration are potent 5-HT 2B agonists [85].”
BackgroundSelf-citationMorgan, D., Kondabolu, K., Kuipers, A., Sakhuja, R., Robertson, K. L., Rowland, N. E., & Booth, R. G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.051 · Cited by 23
“It should be noted that there is no clinical tolerance for activation of 5HT2B receptors as this is associated with severe cardiac valvulopathy and other cardiotoxic effects (Elangbam, 2010; Roth, 2007).”
Adverse effects of benfluorex on heart valves and pulmonary circulation
Szymanski, C., Andréjak, M., Peltier, M., Maréchaux, S., & Tribouilloy, C. M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3642 · Cited by 25
Vahanian, A. S., Iung, B., Piérard, L., Dion, R. A. E., & Pepper, J. (2009) · doi:10.1093/med/9780199566990.003.021 · Cited by 20
Vroonen, L., Lancellotti, P., Garcia, M. T., Dulgheru, R., Rubio-Almanza, M., Maiga, I., Magné, J., Pétrossians, P., Auriemma, R. S., Daly, A., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1177-1 · Cited by 20
Cardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 25
“The molecular mechanisms underlying these proliferative effects involve activation of a number of mitogenic signal transduction pathways by the 5-HT 2B R 133,134 (Fig.”
Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors
Azuaje, J., López, P., Iglesias, A., de la Fuente, R. A., Pérez-Rubio, J. M., García, D., Stępniewski, T. M., García-Mera, X., Brea, J. M., Selent, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11370-2 · Cited by 24
Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis
Fortier, J. H., Pizzarotti, B., Shaw, R. E., Levy, R. J., Ferrari, G. M., & Grau, J. B. (2019) · Heart · doi:10.1136/heartjnl-2018-314403 · Cited by 20
3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands
Porter, M. R., Xiao, H., Wang, J., Smith, S. B., & Topczewski, J. J. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00225 · Cited by 20
Brown, D. G., Smith, G. F., & Wobst, H. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01625 · Cited by 20
Carpenter, J., Wang, Y., Wu, G., Feng, J., Ye, X., Morales, C. L., Broekema, M., Rossi, K. A., Miller, K. J., Murphy, B. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00385 · Cited by 18
Görnemann, T., Hübner, H., Gmeiner, P., HOROWSKI, R., Latté, K. P., Flieger, M., & Pertz, H. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133165 · Cited by 21
“The incidence of the adverse effect (cardiac-valve regurgitation) caused by pergolide is predominantly associated with an involvement of serotonin 5-HT2B receptor activation in cardiac valves (Roth, 2007).”
BackgroundThe human endogenous metabolome as a pharmacology baseline for drug discovery
Bofill, A., Jalencas, X., Oprea, T. I., & Mestres, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.007 · Cited by 17
“A final set of 21 drugs with pKi affinity values, confirmed agonist action to the 5HT2B receptor, and evidence of VHD risk was collected [37–45].”
BackgroundInfluentialRudin, D., McCorvy, J. D., Glatfelter, G. C., Luethi, D., Szöllősi, D., Ljubišić, T., Kavanagh, P. V., Dowling, G., Holy, M., Jäntsch, K., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01221-0 · Cited by 17
“The activation of 5-HT2B receptors has, among others, been linked to cardiac valvulopathy [86, 87].”
BackgroundDisorders of Prolactin Secretion and Prolactinomas
Bronstein, M. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00007-x · Cited by 20
Carcinoid Heart Disease: a Review
Laskaratos, F., Davar, J., & Toumpanakis, C. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01031-z · Cited by 20
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette-Kasic, S., Serri, K., & Serri, O. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.167 · Cited by 17
Schöen, F. J., & Mitchell, R. N. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50017-1 · Cited by 25
Zhang, G., McCorvy, J. D., Shen, S., Cheng, J., Roth, B. L., & Kozikowski, A. P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111626 · Cited by 17
“is essential for the development of potential 5-HT2C-targeted therapeutics [5], as drugs with 5-HT2B agonism may induce potentially life-threatening valvular hypertrophy [6,7], while 5HT2A agonists are hallucinogenic [8].”
BackgroundSelf-citationValvular heart disease in a patient taking 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)
Montastruc, F., Montastruc, G., Vigreux, P., Bruneval, P., Guilbeau‐Frugier, C., Cron, C., Bagheri, H., Delisle, M. B., Lapeyre‐Mestre, M., Pathak, A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04252.x · Cited by 19
Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
Arbouw, M. E. L., Movig, K. L. L., Guchelaar, H., Neef, C., & Egberts, T. C. G. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1084-6 · Cited by 16
Yarman, S., Kurtulmuş, N., & Bilge, A. (2012) · PubMed · Cited by 16
Perez, J. N., Diaz, N. S., Tandon, I., Plate, R., Martindale, C., & Balachandran, K. (2017) · Cardiovascular Engineering and Technology · doi:10.1007/s13239-017-0298-x · Cited by 19
Chanson, P., & Maiter, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00016-7 · Cited by 27
Dodson, A., Mi, K., Russo, D. P., Scott, C. C., Saulnier, M., Snyder, K., & Racz, R. (2021) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2021.107098 · Cited by 19
Tribouilloy, C. M., Maréchaux, S., Jobic, Y., Jeu, A., Éderhy, S., Donal, E., Réant, P., Arnalsteen, E., Boulanger, J., Garban, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht266 · Cited by 16
“a metabolite of methysergide.(24) Interestingly, 5-HT polymorphisms have been observed to be associated with the penetrance of clinical manifestations in a number of neurological diseases.”
BackgroundLorcaserin for Weight Loss: Insights Into US Food and Drug Administration Approval
Miller, L. E. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.08.028 · Cited by 21
Bellis, A. D., Colao, A., Savoia, A., Coronella, C., Pasquali, D., Conte, M., Pivonello, R., Bellastella, A., Sinisi, A. A., Bizzarro, A., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03200.x · Cited by 17
Brennan, P. E., Whitlock, G. A., Ho, D. K. H., Conlon, K. M., & McMurray, G. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.063 · Cited by 16
Kekewska, A., Görnemann, T., Jantschak, F., Glusa, E., & Pertz, H. H. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187906 · Cited by 19
Kolaczynska, K. E., Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794254 · Cited by 18
“…therefore a potential adverse effect to consider for chronic use of substances interacting with this receptor (Rothman et al., 2000; Droogmans et al., 2007; Roth 2007; Doly et al., 2008; Elangbam et al., 2008; Bhattacharyya et al., 2009; Huang et al., 2009; Elangbam 2010; Dawson and Moffatt 2012).”
BackgroundMaréchaux, S., Jeu, A., Jobic, Y., Éderhy, S., Donal, E., Réant, P., Abouth, S., Arnasteen, E., Boulanger, J., Ennezat, P., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.006 · Cited by 15
“This type of 5-HT2B agonist effect has also been reported for ergot alkaloids, ergotamine and methysergide, pergolide, cabergoline, MDMA, ergotamine and methylergonovine, a metabolite of methysergide [2].”
BackgroundUrbán, L., Maciejewski, M., Lounkine, E., Whitebread, S., Jenkins, J. L., Hamon, J., Fekete, A., & Muller, P. Y. (2014) · Toxicology Research · doi:10.1039/c4tx00077c · Cited by 16
Lee, M. J. (2014) · International Journal of Gastroenterology Disorders & Therapy · doi:10.15344/2393-8498/2014/108 · Cited by 13
“In cardiovascular system, activation of 5-HT2B receptors is believed to be necessary to produce 5-HTinduced valvulopathy [37,38].”
Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists
Rouquet, G., Moore, D. E., Spain, M. P., Allwood, D. M., Battilocchio, C., Blakemore, D. C., Fish, P. V., Jenkinson, S. G., Jessiman, A. S., Ley, S. V., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500507v · Cited by 14
Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials
Weissman, N. J., Smith, S. R., Fain, R., Hall, N., & Shanahan, W. R. (2016) · Obesity · doi:10.1002/oby.21695 · Cited by 14
“Previous nonselective serotonergic agents implicated in FDAdefined cardiac valvulopathy have potent activity at the 5-HT2B receptor (8-10).”
BackgroundSerotonin and Cardiovascular Diseases
Monassier, L., & Maroteaux, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-800050-2.00012-7 · Cited by 17
“disease patients treated with pergolide or cabergoline (Antonini & Poewe, 2007; Roth, 2007), which are also 5-HT2B-receptor agonists, but not with lisuride or terguride, which are not (Jahnichen, et al.”
BackgroundPinterová, N., Horsley, R. R., Danda, H., Žídková, M., Lhotková, E., Šíchová, K., Štefková, K., Balíková, M., Kuchař, M., & Páleníček, T. (2020) · Addiction Biology · doi:10.1111/adb.12906 · Cited by 13
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
Schmitz, G. P., & Roth, B. L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00397.2022 · Cited by 13
Self-citationChemistry/structural biology of psychedelic drugs and their receptor(s)
Gumpper, R. H., & Nichols, D. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17361 · Cited by 14
“Chronic activation of the 5-HT 2B receptor has been implicated in the development of valvular heart disease (Ceron et al., 2024; Roth, 2007) perhaps best exemplified by fenfluramine , which was withdrawn from the market because of drug-induced valvular heart disease in about 30% of individuals…”
Heifetz, A., Storer, R. I., McMurray, G., James, T., Morao, I., Aldeghi, M., Bodkin, M. J., & Biggin, P. C. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01045 · Cited by 13
Identification of host interactions for phenotypic antimalarial hits
Spitzmüller, A., & Mestres, J. (2014) · Journal of Cheminformatics · doi:10.1186/1758-2946-6-s1-o12 · Cited by 13
Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson’s disease
Montastruc, F., Moulis, F., Araujo, M., Chebane, L., Rascol, O., & Montastruc, J. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2142-x · Cited by 13
Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity
Sameshima, T., Yukawa, T., Hirozane, Y., Yoshikawa, M., Katoh, T., Hara, H., Yogo, T., Miyahisa, I., Okuda, T., Miyamoto, M., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00128 · Cited by 14
Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice
Saraf, T. S., Felsing, D. E., Armstrong, J. L., Booth, R. G., & Canal, C. E. (2021) · Epilepsy Research · doi:10.1016/j.eplepsyres.2021.106677 · Cited by 14
A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Löndahl, M., Nilsson, A., Lindgren, H. I. V., & Katzman, P. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0584 · Cited by 13
“lisuride) 5-HT2B antagonistic properties has not been reported to be associated with valve disease ( 5 , 6). In contrast to this, ergot dopamine agonists (i.e.”
BackgroundOeda, T., Masaki, M., Yamamoto, K., Mizuta, E., Kitagawa, N., Isono, T., Taniguchi, S., Doi, K., Yaku, H., Yutani, C., et al. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0160-2 · Cited by 13
“…2004; Waller et al. 2005; Peralta et al. 2006; Yamamoto et al. 2006; Junghanns et al. 2007; Schade et al. 2007; Zanettini et al. 2007; Yamashiro et al. 2008), while an association between VHD and dopamine agonists with serotonin 2B receptor agonistic actions has also been established (Roth 2007).”
BackgroundResultInfluentialMolecular Similarity Perception Based on Machine-Learning Models
Gandini, E., Marcou, G., Bonachéra, F., Varnek, A. A., Pieraccini, S., & Sironi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116114 · Cited by 13
“Finally, we queried the ChEMBL 27 database [18,26,27] for molecules that targeted three well-known biological targets: HERG [28], 5HT2B [20], and CYP2D6 [21].”
MethodZhuang, C., Sheng, C., Shin, W. S., Wu, Y., Li, J., Yao, J., Dong, G., Zhang, W., Sham, Y. Y., Miao, Z., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2521 · Cited by 11
“com/oncotarget frequently causes toxicity [13] and adverse effects [14, 15].”
Benfluorex (Mediator®) et atteintes valvulaires
Tribouilloy, C. M., Jeu, A., Maréchaux, S., Jobic, Y., Ruşinaru, D., & Andréjak, M. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.09.001 · Cited by 14
“10 10 [(Figure_2)TD$FIG] C Tribouilloy, A Jeu, S Maréchaux, Y Jobic, D Rusinaru, M Andréjak © 2018 Elsevier Mas synthèse de collagène et de glycosaminoglycanes par l’intermédiaire d’une activation des protéines kinases et des effets du TGFb [6].”
BackgroundKekewska, A., Hübner, H., Gmeiner, P., & Pertz, H. H. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.181255 · Cited by 12
“Evidence has been provided that agonist activity at 5-HT2BRs is a likely molecular mechanism of drug-induced VHD (Roth, 2007).”
BackgroundInfluentialDopamine agonists in the treatment of prolactinoma: are they still first choice?
Ogilvie, M., & Milsom, S. R. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2010.02410.x · Cited by 12
Andrews, M. D., Fish, P. V., Blagg, J., Brabham, T., Brennan, P. E., Bridgeland, A., Brown, A. D., Bungay, P. J., Conlon, K. M., Edmunds, N. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.120 · Cited by 12
The Role Of Cell Biology And Leaflet Remodeling In The Progression Of Heart Valve Disease
Xu, S., & Grande-Allen, K. J. (2010) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-6-1-2 · Cited by 13
“40 the resulting superficial plaque is comprised of a collection of myo fibroblasts within a matrix consisting mainly of collagen, GAGs, and elastin.”
Dopamine agonists and valvular heart disease
Cheung, D. S., & Heaney, A. P. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832d9f64 · Cited by 13
Metadata
- Authors
- Roth, B. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Roth, Bryan L.
- ORCID
- Roth, Bryan L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 6-9
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965258805
- Cited by
- 479
- References
- 7
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 18 · 2020: 17 · 2019: 18 · 2018: 20 · 2017: 19 · 2016: 30 · 2015: 29 · 2014: 25 · 2013: 32 · 2012: 28
- FWCI
- 35.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- fenfluramine, dexfenfluramine, valvular heart disease, drug-induced valvular disease, leaflet thickening, echocardiographic findings
- MeSH terms
- Cabergoline, Antiparkinson Agents, Ergolines, Heart Valve Diseases, Humans, Pergolide, Serotonin Receptor Agonists, Dopamine Agonists, Receptor, Serotonin, 5-HT2B, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.